drugset / Trial / NCT02646475

Metabolic Effects of Angiotensin-(1-7)

NCT02646475

Phase 1 Recruiting 26 enrolled Vanderbilt University
RandomizedCrossoverDouble-blindOther

Summary

The overall purpose of this study is to learn more about the metabolic effects of angiotensin-(1-7) in the insulin resistant state associated with obesity. Pharmacologic approaches to increase angiotensin-(1-7) levels or its actions are currently in development for treatment of metabolic-related diseases such as obesity and type II diabetes, based on findings from animal studies. It is unclear if this peptide contributes to the regulation of metabolism in humans. The investigators will test if angiotensin-(1-7) infusion can improve insulin sensitivity measured by hyperinsulinemic-euglycemic clamp methods in individuals with obesity and insulin resistance. The investigators will also examine for changes in blood pressure and related hemodynamic and hormonal changes following angiotensin-(1-7) infusion.

Timeline

Start
2016-02
Primary completion
2029-12
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject talfirastide Peptide 4 unknown Intravenous
Subject talfirastide Peptide 8 unknown Intravenous
Subject talfirastide Peptide 16 unknown Intravenous